We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$221M
AUM Growth
+$8.65M
Cap. Flow
-$6.33M
Cap. Flow %
-2.87%
Top 10 Hldgs %
71.57%
Holding
93
New
9
Increased
15
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$2.91M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.47M
3
LENZ
LENZ Therapeutics
LENZ
+$2.23M
4
ALKS icon
Alkermes
ALKS
+$1.46M
5
LQDA icon
Liquidia Corp
LQDA
+$1.33M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$4.2M
2
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$2.85M
3
VRNA
Verona Pharma
VRNA
+$2.44M
4
ARDX icon
Ardelyx
ARDX
+$2.42M
5
OABI icon
OmniAb
OABI
+$2.36M

Sector Composition

Rank Sector Weight
1 Healthcare 31.49%
2 Materials 24.07%
3 Financials 19.36%
4 Communication Services 9.05%
5 Industrials 1.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLMT icon
1
Calumet Specialty Products
CLMT
$3.85B
$51.6M 23.39%
3,275,231
-21,963
-0.7% -$279K
APO icon
2
Apollo Global Management
APO
$68.3B
$31.9M 14.47%
225,000
– –
JAAA icon
3
Janus Henderson AAA CLO ETF
JAAA
$29.1B
$25.1M 11.39%
495,254
-56,509
-10% -$2.85M
GOOG icon
4
Alphabet (Google) Class C
GOOG
$4.22T
$19.9M 9.02%
112,220
– –
JPM icon
5
JPMorgan Chase
JPM
$918B
$6.08M 2.76%
20,985
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$5.2M 2.36%
55,000
-33,000
-38% -$2.44M
XERS icon
7
Xeris Biopharma Holdings
XERS
$1.52B
$4.95M 2.24%
1,060,000
-50,000
-5% -$229K
DCGO icon
8
DocGo
DCGO
$63.5M
$4.82M 2.19%
3,070,850
– –
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.89B
$4.42M 2%
80,000
+4,000
+5% +$192K
TVTX icon
10
Travere Therapeutics
TVTX
$5.26B
$3.85M 1.74%
260,000
+32,000
+14% +$530K
CPRX
11
DELISTED
Catalyst Pharmaceutical
CPRX
$3.82M 1.73%
176,000
-36,000
-17% -$850K
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$3.77M 1.71%
426,000
– –
BBIO icon
13
BridgeBio Pharma
BBIO
$16.1B
$3.45M 1.57%
+80,000
New +$2.91M
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$2.01B
$3.3M 1.5%
352,778
+224,778
+176% +$2.47M
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.39B
$2.98M 1.35%
332,625
-127,375
-28% -$1.19M
INZY
16
DELISTED
Inozyme Pharma
INZY
$2.66M 1.21%
666,204
– –
ESGR
17
DELISTED
Enstar Group
ESGR
$2.52M 1.14%
7,500
– –
LENZ
18
LENZ Therapeutics
LENZ
$162M
$2.4M 1.09%
+82,000
New +$2.23M
CSX icon
19
CSX Corp
CSX
$92.7B
$2.28M 1.04%
70,000
– –
AB icon
20
AllianceBernstein
AB
$3.51B
$1.96M 0.89%
48,000
– –
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.82B
$1.89M 0.86%
52,000
+4,000
+8% +$144K
PFE icon
22
Pfizer
PFE
$142B
$1.81M 0.82%
74,537
-180,000
-71% -$4.2M
ACLX
23
DELISTED
Arcellx
ACLX
$1.69M 0.77%
25,700
+10,700
+71% +$666K
ATRC icon
24
AtriCure
ATRC
$1.75B
$1.52M 0.69%
46,443
+21,823
+89% +$709K
TECX
25
Tectonic Therapeutic
TECX
$619M
$1.47M 0.67%
74,000
+34,000
+85% +$689K
1
2 3 4

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
TT
TI-Trust Quincy, Illinois $168M AUM 24.32% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return

David M. Knott Jr's Q2 2025 Portfolio in Review

As of Q2 2025, David M. Knott Jr held 93 positions worth $221M, up 4.1% from $212M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

David M. Knott Jr's Q2 2025 filing shows 9 new, 15 increased, 13 reduced and 8 closed positions. Its largest new stake was BridgeBio Pharma: 80,000 shares worth $3.45M. The largest sale was Pfizer, an estimated $4.2M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 33% a quarter earlier, followed by Materials and Financials.

  • David M. Knott Jr's largest Q2 2025 buy was BridgeBio Pharma: 80,000 shares worth $3.45M.
  • David M. Knott Jr added most to Syndax Pharmaceuticals in Q2 2025, an estimated $2.47M increase.
  • David M. Knott Jr's biggest Q2 2025 reduction was Pfizer, cutting an estimated $4.2M.
  • David M. Knott Jr fully exited Ardelyx in Q2 2025, selling an estimated $2.42M.
  • David M. Knott Jr's ten largest holdings make up 72% of its $221M portfolio in Q2 2025.
  • David M. Knott Jr opened 9 new positions and closed 8 in Q2 2025.
  • David M. Knott Jr's portfolio value rose 4.1% quarter-over-quarter to $221M.

Based on David M. Knott Jr's 13F filing for Q2 2025, filed 11 Aug 2025.